8 hours ago
1
appledesign/iStock via Getty Images
- Centessa Pharmaceuticals (NASDAQ:CNTA) said on Monday that it has received approval from the U.S. FDA to start a phase 1 clinical trial of a neuropeptide, ORX142, a new treatment for nerve disorders.
- ORX142 is a drug that targets the OX2R
English (US) ·